Cardiovascular Pharmaceutical Market Trends, 2007 to 2010

The global cardiovascular market grew to US$89.7 billion in 2005, a year-on-year increase of 9.6%.

The global cardiovascular market is forecast to expand to US$116.3 billion in 2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in cardiovascular market growth between 2003 and 2005 is forecast to continue through to 2010. While continued changes in demographics and lifestyle will continue to drive cardiovascular sales forward, growth rates will be limited by continued patent expiries for major products and a dearth of novel therapies being introduced.

Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for cardiovascular disorders including:

- Coronary heart disease

- Cerebrovascular disease

- Peripheral arterial disease

- Rheumatic heart disease

- Congenital heart disease

- Deep vein thrombosis and pulmonary embolism

This comprehensive report, from URCH Publishing, delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.

Key findings from the report include:

The global market for cardiovascular patients will increase to 251 million in 2010, with the greatest rate of growth forecast for the US market.

The anti-hypertensives drug class dominates the global cardiovascular market with a market share of nearly 50%.

Of the top 20 products by global cardiovascular sales in 2005, all 20 generated annual sales in excess of US$1 billion.

The top 20 products in 2005 contributed sales of US$59.3 billion accounting for 66.1% of the total cardiovascular market.

A total of 14 pharmaceutical companies were identified as having generated cardiovascular sales in excess of US$1 billion in 2005.

The leading cardiovascular drug projected to achieve the greatest growth over the next five years is Takeda/ AstraZeneca's Blopress/ Atacand (candesartan) with a CAGR of 9.0%

This report provides key information needed in your business including:

Sales forecast for top ten companies providing cardiovascular treatment medicines.

Analysis of leading cardiovascular products likely to loose patent protection in the next ten years.

Sales forecasts to 2010 for the top ten cardio medicines and forecasts by drug class.

Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.

Breakdown of the major market trends and business opportunities

In-depth coverage of the following companies' cardio market presence: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier.

Use This Report To: 1. Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.

2. Indentify areas of potential pharmaceutical market growth and good opportunities for delivering successful sales growth

3. Support your internal business planning processes by using an external perspective founded on detailed analysis and solid market forecasts.

The 112 page publication contains 40 Figures and 46 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:

- pharmaceutical company corporate planning,

- sales and marketing strategy,

- portfolio management, and,

- market and sales forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future cardiovascular market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cardiovascular market trends.

About the author: Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School.

Title Cardiovascular Pharmaceutical Market Trends, 2007 to 2010

Sub title Key market forecasts and growth opportunities

Author S Seget

Publication date August 2007

Pages 112

Format: PDF

Table of Contents
Price: $1,845.00 / GBP959.40